Blair William & Co. IL Has $6.04 Million Position in Becton, Dickinson and Company $BDX

Key Points

• Blair William & Co. IL has reduced its stake in Becton, Dickinson and Company (BDX) by 6.0%, now holding 35,036 shares valued at approximately $6.04 million.
• Institutional investors currently own 86.97% of Becton, Dickinson's stock, indicating strong institutional interest in the company.
• Equities research analysts have a consensus rating of "Hold" on BDX shares, with an average price target of $205.40, reflecting a cautious outlook.

Blair William & Co. IL reduced its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 6.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,036 shares of the medical instruments supplier's stock after selling 2,230 shares during the period. Blair William & Co. IL's holdings in Becton, Dickinson and Company were worth $6,035,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of BDX. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. GAMMA Investing LLC increased its stake in Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after purchasing an additional 748 shares in the last quarter. SG Americas Securities LLC increased its stake in Becton, Dickinson and Company by 53.5% in the first quarter. SG Americas Securities LLC now owns 9,088 shares of the medical instruments supplier's stock valued at $2,082,000 after purchasing an additional 3,168 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Becton, Dickinson and Company by 1.0% in the first quarter. Assenagon Asset Management S.A. now owns 8,047 shares of the medical instruments supplier's stock valued at $1,843,000 after purchasing an additional 79 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC increased its stake in Becton, Dickinson and Company by 30.0% in the first quarter. Elevation Point Wealth Partners LLC now owns 3,947 shares of the medical instruments supplier's stock valued at $904,000 after purchasing an additional 911 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on BDX shares. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Royal Bank Of Canada started coverage on shares of Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 target price for the company. Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Wells Fargo & Company increased their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Finally, Argus increased their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $205.40.

Becton, Dickinson and Company Stock Down 1.4%

Shares of BDX stock opened at $186.41 on Monday. The firm has a fifty day moving average of $190.07 and a 200-day moving average of $185.73. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a market capitalization of $53.43 billion, a price-to-earnings ratio of 33.53, a P/E/G ratio of 1.46 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares of the company's stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,023 shares of company stock valued at $562,036 in the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.